Hofseth BioCare Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jon Odegard

Algemeen directeur

NOK 2.8m

Totale compensatie

Percentage CEO-salaris	58.6%
Dienstverband CEO	2.3yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	3.8yrs
Gemiddelde ambtstermijn bestuur	2.5yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jon Odegard's beloning veranderd ten opzichte van Hofseth BioCare's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-NOK 133m
Jun 30 2024	n/a	n/a	-NOK 121m
Mar 31 2024	n/a	n/a	-NOK 98m
Dec 31 2023	NOK 3m	NOK 2m	-NOK 107m
Sep 30 2023	n/a	n/a	-NOK 93m
Jun 30 2023	n/a	n/a	-NOK 105m
Mar 31 2023	n/a	n/a	-NOK 140m
Dec 31 2022	NOK 3m	NOK 1m	-NOK 137m
Sep 30 2022	n/a	n/a	-NOK 136m
Jun 30 2022	n/a	n/a	-NOK 139m
Mar 31 2022	n/a	n/a	-NOK 135m
Dec 31 2021	n/a	n/a	-NOK 126m
Sep 30 2021	n/a	n/a	-NOK 120m
Jun 30 2021	n/a	n/a	-NOK 115m
Mar 31 2021	n/a	n/a	-NOK 111m
Dec 31 2020	NOK 2m	NOK 695k	-NOK 102m
Sep 30 2020	n/a	n/a	-NOK 104m
Jun 30 2020	n/a	n/a	-NOK 90m
Mar 31 2020	n/a	n/a	-NOK 86m
Dec 31 2019	NOK 2m	NOK 660k	-NOK 89m
Sep 30 2019	n/a	n/a	-NOK 79m
Jun 30 2019	n/a	n/a	-NOK 81m
Mar 31 2019	n/a	n/a	-NOK 83m
Dec 31 2018	NOK 2m	NOK 702k	-NOK 85m
Sep 30 2018	n/a	n/a	-NOK 74m
Jun 30 2018	n/a	n/a	-NOK 66m
Mar 31 2018	n/a	n/a	-NOK 66m
Dec 31 2017	NOK 2m	NOK 2m	-NOK 16m

Compensatie versus markt: De totale vergoeding ($USD 254.15K ) Jon } ligt onder het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 472.15K ).

Compensatie versus inkomsten: De vergoeding van Jon is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Jon Odegard

2.3yrs

Tenure

NOK 2,841,000

Compensatie

Mr. Jon Olav Odegard had been Chief Financial Officer of Hofseth BioCare ASA since August 29, 2016 until 2022 and serves as its Chief Executive Officer since August 1, 2022 and was its Chief Executive Offi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jon Odegard	Chief Executive Officer	2.3yrs	NOK 2.84m	geen gegevens
Bomi Framroze	Chief Scientific Officer	14.8yrs	NOK 9.44m	1.26% € 583.9k
James Berger	Chief Commercial Officer	3.8yrs	NOK 501.00k	geen gegevens
Angelika Florvaag	Chief Quality Officer	3.8yrs	NOK 1.26m	geen gegevens

3.8yrs

Gemiddelde duur

Ervaren management: Het managementteam van HBQ wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Crawford Linden Currie	Director	2.8yrs	NOK 96.00k	geen gegevens
Roger Hofseth	Director	2.3yrs	NOK 96.00k	geen gegevens
Maria Bech	Director	less than a year	geen gegevens	geen gegevens
Amy Novogratz	Independent Director	2.9yrs	geen gegevens	geen gegevens
Christoph Baldegger	Independent Director	9.8yrs	NOK 116.00k	geen gegevens
Linda Hoff	Chair of the Board	less than a year	geen gegevens	geen gegevens

2.5yrs

Gemiddelde duur

53yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van HBQ wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.5 jaar), wat duidt op een nieuw bestuur.

Hofseth BioCare Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Hofseth BioCare ASA, Annual General Meeting, May 23, 2025

Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO

Less than half of directors are independent

Hofseth BioCare ASA Announces Board Changes

Hofseth BioCare ASA Announces Executive Changes

Chief Executive Officer recently bought €48k worth of stock

Recent updates

Hofseth BioCare ASA, Annual General Meeting, May 23, 2025

Third quarter 2024 earnings released: kr0.09 loss per share (vs kr0.057 loss in 3Q 2023)

Hofseth BioCare ASA to Report Q4, 2025 Results on Feb 13, 2026

Hofseth BioCare ASA to Report First Half, 2025 Results on Aug 22, 2025

Hofseth Biocare Asa Announces Resignation of Christel Elise Kanli as CFO

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: kr0.04 loss per share (vs kr0.015 profit in 2Q 2023)

Less than half of directors are independent

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Hofseth BioCare ASA Announces Board Changes

Full year 2023 earnings released: kr0.27 loss per share (vs kr0.37 loss in FY 2022)

Now 31% undervalued after recent price drop

Hofseth BioCare ASA to Report Q4, 2024 Results on Feb 14, 2025

Third quarter 2023 earnings released: kr0.06 loss per share (vs kr0.09 loss in 3Q 2022)

New minor risk - Market cap size

Second quarter 2023 earnings released: EPS: kr0.015 (vs kr0.079 loss in 2Q 2022)

New minor risk - Market cap size

Hofseth Biocare ASA Announces the Online Publication of Its Abstract

First quarter 2023 earnings released: kr0.10 loss per share (vs kr0.10 loss in 1Q 2022)

Full year 2022 earnings released: kr0.37 loss per share (vs kr0.35 loss in FY 2021)

Hofseth BioCare ASA to Report Fiscal Year 2022 Results on Mar 31, 2023

Third quarter 2022 earnings released: kr0.09 loss per share (vs kr0.11 loss in 3Q 2021)

Hofseth BioCare ASA's Progo Bioactive Peptides Now Is A "New Dietary Ingredient" for the US FDA

Second quarter 2022 earnings released: kr0.08 loss per share (vs kr0.069 loss in 2Q 2021)

Hofseth BioCare ASA Announces Executive Changes

First quarter 2022 earnings released: kr0.10 loss per share (vs kr0.075 loss in 1Q 2021)

Full year 2021 earnings released: kr0.35 loss per share (vs kr0.31 loss in FY 2020)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Hofseth Biocare ASA Successfully Receive New Dietary Ingredient (NDI) Status from the US FDA

Third quarter 2021 earnings released: kr0.11 loss per share (vs kr0.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.07 loss per share (vs kr0.062 loss in 2Q 2020)

Hofseth BioCare ASA Provides Earnings Guidance for the Second Half of 2021 and Next Year 2022

First quarter 2021 earnings released: kr0.08 loss per share (vs kr0.055 loss in 1Q 2020)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

Full year 2020 earnings released: kr0.31 loss per share (vs kr0.29 loss in FY 2019)

New 90-day high: €0.91

Chief Executive Officer recently bought €48k worth of stock

Chief Executive Officer recently bought €48k worth of stock

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 39.999995 million.

Hofseth Biocare ASA and Tenet Partners Initiate A Long-Term Collaboration to Build A Global Brand and Launch HBC Own Branded Consumer Health Products

Hofseth BioCare ASA and DKSH Announces A Pan-Asian Exclusive Collaboration for Distribution of HBC Branded Products Including Across China, India, Japan & Korea

Hofseth Biocare Asa Signs Exclusive Distribution Agreement with Leading Speciality Chemicals and Ingredients Distributor IMCD

New 90-day high: €0.82

Hofseth Biocare ASA Hires Andy Gill as VP from January 2021

Hofseth BioCare ASA, Annual General Meeting, Apr 23, 2021

Hofseth Biocare ASA Approves Appointment of Christoph Baldegger as New Member of the Audit Committee

Third quarter earnings released

New 90-day low: €0.69

HBC Receives Approval from Health Canada for Qualified Health Claims Focused on Maintaining Healthy Levels of Ferritin and Hemoglobin and the Blood Components Required for Oxygen Transport

Hofseth BioCare ASA has completed a Follow-on Equity Offering in the amount of NOK 200 million.

Hofseth Biocare ASA's Progo’s Bioactive Peptides to Support Healthy Iron Levels to Be Launched in the US

Hofseth BioCare ASA Announces the First Part of its Accelerated Phase 2 Trial of Cardio™ Soft Gels for the Treatment of Patients with COVID-19

New 90-day low - €0.75

First half earnings released

Hofseth BioCare ASA (OB:HBC) acquired a 34% stake in Atlantic Delights Ltd. for $0.7 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd